Microsatellite instability and loss of heterozygosity at chromosomal location 18q: Pospective evaluation of biomarkers for stages II and III colon cancer - A study of CALGB 9581 and 89803

Journal of Clinical Oncology

Volumn 29, Issue 23, 2011, Pages 3153-3162

  Bertagnolli, Monica M ^a,b   Redston, Mark ^a   Compton, Carolyn C ^e   Niedzwiecki, Donna ^c   Mayer, Robert J ^b   Goldberg, Richard M ^d   Colacchio, Thomas A ^f   Saltz, Leonard B ^g   Warren, Robert S ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CHROMOSOME 18Q; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 18; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE INSTABILITY; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 80051820416     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.0092     Document Type: Article

References (35)

1. Vogelstein B., Fearon E.R., Hamilton S.R., et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
2. Sargent D.J., Marsoni S., Monges G., et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
3. Thibodeau S., Bren G., Schaid D.: Microsatellite instability in cancer of the proximal colon. Science 260:616-619, 1993
4. Watanabe T., Wu T.T., Catalano P.J., et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1208, 2001
5. Samowitz W.S., Curtin K., Ma K.N., et al: Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10:917-932, 2001
6. Ribic C.M., Sargent D.J., Moore M.J., et al: Tumor microsatellite- instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003 (Pubitemid 36859476)
7. Sargent D.J., Marsoni S., Thibodeau S.N., et al: Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer: A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 26:180s, 2008 (suppl; abstr 4008)
8. Kerr D., Gray R., Quirke P., et al: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 27:15s, 2009 (suppl; abstr 4000)
9. Jen J., Kim H., Piantadosi S., et al: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213-221, 1994 (Pubitemid 24226678)
10. Saltz L.B., Niedzwiecki D., Hollis D., et al: Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 25:3456-3461, 2007 (Pubitemid 47310883)
11. Niedzwiecki D., Bertagnolli M.M., Warren R.S., et al: Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results of CALGB 9581. J Clin Oncol 29:3146-3152, 2011
12. Chang S.C., Lin J.K., Lin T.C., et al: Loss of heterozygosity: An independent prognostic factor of colorectal cancer. World J Gastroenterol 11:778-784, 2005
13. Zauber N.P., Wang C., Lee P.S., et al: Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. J Clin Pathol 57:938-942, 2004 (Pubitemid 39208244)
14. Ogunbiyi O.A., Goodfellow P.J., Herforth K., et al: Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16:427-433, 1998 (Pubitemid 28135583)
15. Jernvall P., Mäkinen M.J., Karttunen T.J., et al: Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 79:903-908, 1998 (Pubitemid 29082124)
16. Choi S.W., Lee K.J., Bae Y.A., et al: Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res 8:2311-2322, 2002 (Pubitemid 34753606)
17. Halling K.C., French A.J., McDonnell S.K., et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295-1303, 1999 (Pubitemid 29387571)
18. Barratt P.L., Seymour M.T., Stenning S.P., et al: DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study. Lancet 360:1381-1391, 2002 (Pubitemid 35341303)
19. Ogino S., Nosho K., Irahara N., et al: Prognostic significance and molecular associations of 18q loss of heterozygosity: A cohort study of microsatellite stable colorectal cancers. J Clin Oncol 27:4591-4598, 2009
20. Popat S., Zhao D., Chen Z., et al: Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective blinded analysis of 280 patients. Anticancer Res 27:627-634, 2007
21. Roth A.D., Tejpar S., Yan P., et al: Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 27:169s, 2009 (suppl; abstr 4002)
22. Martínez-López E., Abad A., Font A., et al: Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 114:1180-1187, 1998 (Pubitemid 28243903)
23. Lanza G., Matteuzzi M., Gafá R., et al: Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 79:390-395, 1998 (Pubitemid 28359738)
24. Bertagnolli M.M., Niedzwiecki D., Compton C.C., et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27:1814-1821, 2009
25. Fearon E.R., Cho K.R., Nigro J.M., et al: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49-56, 1990
26. Alazzouzi H., Alhopuro P., Salovaara R., et al: SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11:2606-2611, 2005 (Pubitemid 40569460)
27. Eppert K., Scherer S.W., Ozcelik H., et al: MADR2 maps to 18q21 and encodes a TGF-beta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543-552, 1996 (Pubitemid 26299486)
28. Shibata D., Reale M.A., Lavin P., et al: The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727-1732, 1996 (Pubitemid 26399347)
29. Kern S.E., Fearon E.R., Kasper W.F., et al: Allelic loss in colorectal carcinoma. JAMA 261:3099-3103, 1989 (Pubitemid 19133351)
30. Font A., Abad A., Monzó M., et al: Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 44:549-557, 2001 (Pubitemid 32336428)
31. Diep C.B., Thorstensen L., Meling G.I., et al: Genetic tumor markers with prognostic impact in Dukes' states B and C colorectal cancer patients. J Clin Oncol 21:820-829, 2003 (Pubitemid 46606441)
32. Laurent-Puig P., Olschwang S., Delattre O., et al: Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102:1136-1141, 1992
33. Carethers J.M., Hawn M.T., Greenson J.K., et al: Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 114:1188-1195, 1998 (Pubitemid 28243904)
34. Lindforss U., Fredholm H., Papadoglannakis N., et al: Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma. Cancer 88:2661-2667, 2000 (Pubitemid 30417925)
35. Bisgaard M.L., Jäger A.C., Dalgaard P., et al: Allelic loss of chromosome 2p21-16.3 is associated with reduced survival in sporadic colorectal cancer. Scand J Gastroenterol 36:405-409, 2001 (Pubitemid 32250737)